Heart disease remains the leading cause of death in the United States, with cardiovascular disease accounting for more than 940,000 deaths in 2022, according to the American Heart Association. Into this persistent healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that applies artificial intelligence, epigenetics, and genetics to detect coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
The scale of the problem is staggering: annual healthcare costs for cardiovascular conditions are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. Cardio Diagnostics' approach offers a defensible clinical position through earlier detection with high sensitivity. The company's recent commercial and regulatory milestones underscore its potential to reshape cardiovascular diagnostics.
Cardio Diagnostics' technology leverages epigenetic markers—chemical modifications to DNA that influence gene expression—combined with AI algorithms to identify coronary heart disease risk. This method can detect subtle changes that traditional tools like stress tests or angiograms might miss, enabling earlier intervention. The company's platform is designed to be scalable, requiring only a blood draw, which could facilitate widespread screening.
The company's newsroom provides updates on its progress, available at https://ibn.fm/CDIO. Additionally, the full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
Forward-looking statements in this article are subject to risks and uncertainties, as detailed in the company's filings with the SEC, including the Risk Factors section of its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on these forward-looking statements, and the company undertakes no duty to update them unless required by law.
